Literature DB >> 25761924

Reviewing the recommendations for lupus in children.

Zehra Serap Arıcı1, Ezgi Deniz Batu, Seza Ozen.   

Abstract

Systemic lupus erythematosus (SLE) is an autoimmune connective tissue disorder with severe morbidity and mortality and diverse systemic involvement. Disease onset occurs during childhood in approximately 15 % of patients with SLE. It is important to treat the attacks adequately and prevent further flares for favorable long-term outcomes. The aim of effective disease management with early immunosuppression is to achieve symptomatic resolution and improvement in the quality of life by maintaining sustained remission and thereby preventing tissue damage. Adult literature on SLE management has evolved considerably over the past few decades based on observations from clinical studies investigating different immunosuppressive agents. We lack well-designed randomized controlled trials in children with SLE, thus we mainly depend on adult literature. Here, we review the literature for the current management of SLE in children and we present the recommendations and suggestions with the level of evidence.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25761924     DOI: 10.1007/s11926-014-0489-5

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  148 in total

1.  Increasing incidence of childhood class V lupus nephritis.

Authors:  J M Sorof; M D Perez; E D Brewer; E P Hawkins; R W Warren
Journal:  J Rheumatol       Date:  1998-07       Impact factor: 4.666

2.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

Review 3.  Management of antiphospholipid antibody syndrome: a systematic review.

Authors:  Wendy Lim; Mark A Crowther; John W Eikelboom
Journal:  JAMA       Date:  2006-03-01       Impact factor: 56.272

4.  Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis.

Authors:  Mary Anne Dooley; David Jayne; Ellen M Ginzler; David Isenberg; Nancy J Olsen; David Wofsy; Frank Eitner; Gerald B Appel; Gabriel Contreras; Laura Lisk; Neil Solomons
Journal:  N Engl J Med       Date:  2011-11-17       Impact factor: 91.245

Review 5.  Neuropsychiatric manifestations in pediatric systemic lupus erythematosus: a 20-year study.

Authors:  H H Yu; J H Lee; L C Wang; Y H Yang; B L Chiang
Journal:  Lupus       Date:  2006       Impact factor: 2.911

Review 6.  Lupus arthritis--do we have a clinically useful classification?

Authors:  Elisabeth M A Ball; Aubrey L Bell
Journal:  Rheumatology (Oxford)       Date:  2011-12-15       Impact factor: 7.580

Review 7.  Understanding the epidemiology and progression of systemic lupus erythematosus.

Authors:  Guillermo J Pons-Estel; Graciela S Alarcón; Lacie Scofield; Leslie Reinlib; Glinda S Cooper
Journal:  Semin Arthritis Rheum       Date:  2009-01-10       Impact factor: 5.532

8.  Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials.

Authors:  Susan Manzi; Jorge Sánchez-Guerrero; Joan T Merrill; Richard Furie; Dafna Gladman; Sandra V Navarra; Ellen M Ginzler; David P D'Cruz; Andrea Doria; Simon Cooper; Z John Zhong; Douglas Hough; William Freimuth; Michelle A Petri
Journal:  Ann Rheum Dis       Date:  2012-05-01       Impact factor: 19.103

9.  Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial.

Authors:  Frédéric A Houssiau; David D'Cruz; Shirish Sangle; Philippe Remy; Carlos Vasconcelos; Radmila Petrovic; Christoph Fiehn; Enrique de Ramon Garrido; Inge-Magrethe Gilboe; Maria Tektonidou; Daniel Blockmans; Isabelle Ravelingien; Véronique le Guern; Geneviève Depresseux; Loïc Guillevin; Ricard Cervera
Journal:  Ann Rheum Dis       Date:  2010-09-10       Impact factor: 19.103

10.  Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS).

Authors:  Maria J Cuadrado; Maria L Bertolaccini; Paul T Seed; Maria G Tektonidou; Angeles Aguirre; Luisa Mico; Caroline Gordon; Guillermo Ruiz-Irastorza; Maria V Egurbide; Antonio Gil; Gerard Espinosa; Frederic Houssiau; Anisur Rahman; Helena Martin; Neil McHugh; Maria Galindo; Mohammed Akil; Mary C Amigo; Veronica Murru; Munther A Khamashta
Journal:  Rheumatology (Oxford)       Date:  2013-10-04       Impact factor: 7.580

View more
  4 in total

1.  Macrophage activation syndrome in children with systemic juvenile idiopathic arthritis and systemic lupus erythematosus.

Authors:  Selin Aytaç; Ezgi Deniz Batu; Şule Ünal; Yelda Bilginer; Mualla Çetin; Murat Tuncer; Fatma Gümrük; Seza Özen
Journal:  Rheumatol Int       Date:  2016-08-10       Impact factor: 2.631

Review 2.  A Roadmap of In Vitro Models in Osteoarthritis: A Focus on Their Biological Relevance in Regenerative Medicine.

Authors:  Isabella Bartolotti; Livia Roseti; Mauro Petretta; Brunella Grigolo; Giovanna Desando
Journal:  J Clin Med       Date:  2021-04-28       Impact factor: 4.241

Review 3.  Childhood Lupus--Diagnosis and Management.

Authors:  Sujata Sawhney
Journal:  Indian J Pediatr       Date:  2016-01-05       Impact factor: 5.319

4.  How the COVID-19 pandemic has influenced pediatric rheumatology practice: Results of a global, cross-sectional, online survey.

Authors:  Ezgi Deniz Batu; Lovro Lamot; Erdal Sag; Seza Ozen; Yosef Uziel
Journal:  Semin Arthritis Rheum       Date:  2020-09-28       Impact factor: 5.532

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.